title: Testing of the Biocan B inj. ad us. vet. vaccine and development of the new recombinant vaccine against canine borreliosis.
abstract: Verification of the efficacy of Biocan B inj. ad us. vet. (Bioveta, a.s.) was done by challenge testing. Ticks collected in the nature were used as natural vectors of the infection. Six beagles and two control ones were used in the test. Formation of outer surface protein A specific antibodies (OspA antibodies) and borrelia specific immonoglobulins (IgG) was measured by Western blot and EIA in the sera samples. The tissue samples were used for detection of borreliae by cultivation method and dark field microscopy (DFM). Formation of IgG antibodies and OspA antibodies after vaccination was observed. The maximum titer level of antibodies was reached between 21. and 49. day after vaccination and then slowly decreased. Presence of borreliae was detected only in skin biopsies of non-vaccinated dogs. The post mortem tissue samples showed presence of borreliae in all of the samples of the non-vaccinated dogs. The tissues of the vaccinated dogs were not infected with borreliae, except for two samples of dog with low titer levels of OspA antibodies. The development of the new vaccine is based on preparation of recombinant outer surface proteins (e.g. rOspA and rOspC) of B. afzelii, B. burgdorferi and B. garinii origin. Chosen recombinant proteins were successfully expressed in E. coli. The obtained purified proteins are currently being tested on laboratory BALB/c mice. Formation of specific antibodies against some recombinant proteins has been confirmed. These proteins are suitable candidates for preparation of a vaccine prototype and they will be subsequently used in challenge tests.
authors.affiliation: Bioveta, a.s. Komenského 212, Ivanovice na Hané, Czech Republic.
authors.forename: Jana
authors.initials: J
authors.lastname: Tuhácková
authors.forename: Jana
authors.initials: J
authors.lastname: Bĕláková
authors.forename: Michal
authors.initials: M
authors.lastname: Krupka
authors.forename: Jirí
authors.initials: J
authors.lastname: Neperený
authors.forename: Josef
authors.initials: J
authors.lastname: Chumela
authors.forename: Evzen
authors.initials: E
authors.lastname: Weigl
authors.forename: Vladimír
authors.initials: V
authors.lastname: Vrzal
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000954:Antigens, Surface / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology; D001899:Borrelia Infections / Q000517:prevention & control / Q000662:veterinary*; D015748:Borrelia burgdorferi Group / Q000276:immunology; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control*; D004285:Dogs; D008074:Lipoproteins / Q000276:immunology; D022123:Lyme Disease Vaccines / Q000276:immunology*; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; D022123:Lyme Disease Vaccines; C072045:OspA protein; D014614:Vaccines, Synthetic